Immunotherapy company Centauri Therapeutics has extended its Series A financing to £30 million ($40.6 million) to support its lead candidate targeting Gram-negative bacterial infections.  The funding was extended thanks to a £6m ($8.1 million) investment from the AMR Action Fund. The financing from AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to investing […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!